IOBT
MaterialsIO Biotech, Inc. Common Stock
$0.05+0.00 (+0.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IOBT Today?
No stock-specific AI insight has been generated for IOBT yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$3M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding71.9M
IOBT News
21 articles- Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers BankruptcyBenzinga·Apr 3, 2026
- Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO BiotechYahoo Finance·Feb 18, 2026
- Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom FishingYahoo Finance·Feb 13, 2026
- IO Biotech Provides Corporate UpdateYahoo Finance·Jan 30, 2026
- Piper downgrades IO Biotech amid strategic alternatives evaluationYahoo Finance·Jan 27, 2026
- BC-Most Active StocksYahoo Finance·Jan 22, 2026
- Moderna cancer vaccine holds up; IO Biotech considers a saleBiopharmadive·Jan 21, 2026
- IO Biotech Announces Exploration of Strategic AlternativesYahoo Finance·Jan 21, 2026
- IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsYahoo Finance·Dec 15, 2025
- IO Biotech Announces Participation in Upcoming December Investor ConferencesYahoo Finance·Nov 26, 2025
- IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's WhyYahoo Finance·Nov 19, 2025
- IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business HighlightsYahoo Finance·Nov 14, 2025
- IO Biotech Announces Participation in Upcoming Investor ConferencesYahoo Finance·Nov 12, 2025
- IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Yahoo Finance·Nov 7, 2025
- IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025Yahoo Finance·Oct 20, 2025
- FDA official’s comments spark Aurinia sell-off; Halozyme buys a biotechBiopharmadive·Oct 1, 2025
- IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley SaysYahoo Finance·Sep 30, 2025
- IO Biotech Provides Update Following Pre-BLA Meeting with FDAYahoo Finance·Sep 29, 2025
- IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025Yahoo Finance·Sep 23, 2025
- IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Sep 3, 2025
- H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14Yahoo Finance·Aug 26, 2025
All 21 articles loaded
Price Data
Open$0.00
Previous Close$0.05
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$3M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding71.9M
About IO Biotech, Inc. Common Stock
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security Type—
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—